The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in the Asia Pacific is estimated to value USD 625.94 million by 2026 from USD 427.99 million in 2021, projecting a CAGR of 7.9% from 2021 to 2026.
Acute Ischemic stroke can be defined as loss of function in certain parts of the brain due to a lack of blood supply to the brain.
The Asia Pacific is the most promising market for Acute Ischemic Stroke Diagnosis and treatment owing to rising prevalence of acute ischemic stroke cases, technological advancements in surgical procedures along with rising aging population, increasing demand for minimally invasive procedures and growth in healthcare spending. High population base and growing incidence of cardiovascular are also major factors driving the market growth whereas excessive use of medication for the treatment of ischemic stroke and a high cost of surgical procedures are some of the factors restraining the market growth.
This research report on the APAC Acute Ischemic Stroke Treatment & Diagnosis Market is segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
By Country:
On the basis of surgery type, Carotid Endarterectomy is the largest segment accounting for a share of approximately XX% due to its high success rate, short treatment duration, and easy availability.
On the basis of region, Asia-Pacific is the most promising market for acute ischemic stroke diagnosis owing to the increasing number of patients with cardiac-related problems such as ischemic stroke. Manufacturers across various geographies are expanding their operations in the Asia-Pacific region as these regions hold immense potential for the market growth.
Major players playing a crucial role in the APAC Acute Ischemic Stroke Treatment & Diagnosis Market profiled in this report are Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.) and Hitachi, Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Type
5.1.1 Computed Tomography
5.1.2 Magnetic Resonance Imaging
5.1.3 Ultrasound
5.1.4 Cerebral angiography
5.1.5 Nuclear Imaging
5.2 Surgery Type
5.2.1 Carotid Endarterectomy
5.2.2 Angioplasty
5.2.3 Endovascular Mechanical Thrombectomy
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Covidien plc
8.3 Johnson & Johnson
8.4 Penumbra, Inc.
8.5 Philips Healthcare
8.6 GE Healthcare
8.7 Hitachi, Ltd.
8.8 Siemens Healthcare
8.9 Stryker Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
